Evidence map›Paper›PMID 30962503›Full record

Trial reportBone marrow transplantation2019

Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function.

M Hasib Sidiqi, Kalyan Nadiminti, Abdullah S Al Saleh, Kapil Meleveedu, Francis K Buadi, Angela Dispenzieri, Rahma Warsame, Martha Q Lacy, David Dingli, Nelson Leung and 6 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 1 institution in 2 countries.

M Hasib SidiqiDivision of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.
Kalyan NadimintiDivision of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.
Abdullah S Al SalehDivision of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.
Kapil MeleveeduDivision of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.
Francis K BuadiDivision of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.
Angela DispenzieriDivision of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.
Rahma WarsameDivision of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.
Martha Q LacyDivision of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.
David DingliDivision of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.
Nelson LeungDivision of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-5651-1411
Wilson I GonsalvesDivision of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.
Prashant KapoorDivision of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.
Taxiarchis V KourelisDivision of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.
William J HoganDivision of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-5841-4105
Shaji K KumarDivision of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-5392-9284
Morie A GertzDivision of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA. gertz.morie@mayo.edu.
Mayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We retrospectively reviewed the impact of impaired renal function (eGFR < 45 ml/min/SA) on post-transplant outcomes in patients receiving ASCT for AL amyloidosis. Patients were grouped into two cohorts, those with normal renal function (NRF) eGFR ≥ 45 ml/min (n = 568) and those with impaired renal function (IRF) eGFR < 45 ml/min (n = 87). Patients with IRF had higher renal stage (>Stage 1: 100% IRF vs 37% NRF, p < 0.0001) and the majority received conditioning with melphalan <200 mg/m

Indexed as

Hematopoietic Stem Cell TransplantationImmunoglobulin Light-chain AmyloidosisRenal InsufficiencyTransplantation ConditioningAdultAgedAutograftsDisease-Free SurvivalFemaleHumansMaleMelphalanMiddle AgedRenal DialysisSurvival RateMelphalan

Identifiers

PMID30962503
OpenAlexW2940292183

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.